Lantern Pharma's AI Platform Shows Promise in Lung Cancer Treatment

Lantern Pharma Inc. (NASDAQ: LTRN) has announced a notable achievement in its ongoing Phase 2 HARMONIC(TM) trial, where a patient with advanced non-small cell lung cancer (NSCLC) achieved a complete response after treatment with LP-300, a compound optimized through the company's proprietary AI platform, RADR(R). This development is significant as the patient had not responded to three prior lines of treatment, including immunotherapy and targeted kinase inhibitors, and has remained in remission for over two years.

The success of LP-300 in this trial underscores the potential of artificial intelligence in revolutionizing oncology drug development. Lantern Pharma's RADR(R) platform leverages AI and machine learning to rapidly identify drug candidates and design targeted trials based on genomic and biomarker data, offering hope for patients with limited treatment options.

Non-small cell lung cancer in never-smokers represents a growing global health challenge, with an estimated annual market need exceeding $4 billion. The positive outcome from the HARMONIC(TM) trial not only highlights the efficacy of LP-300 in this difficult-to-treat population but also demonstrates the broader applicability of AI in addressing unmet medical needs.

For more information on Lantern Pharma's innovative approach to drug development, visit https://ibn.fm/II6O6. Investors seeking the latest updates on Lantern Pharma can find more information in the company's newsroom at https://ibn.fm/LTRN.